EIT-URBAN-MOBILITY
16.11.2021 09:02:12 CET | Business Wire | Press release
Tomorrow.Mobility World Congress (TMWC) is a new global event, co-organised by Fira de Barcelona and EIT Urban Mobility, focused on promoting the design and adoption of new sustainable urban mobility models. TMWC is being launched to create a global benchmark in the field of mobility and to go beyond a one-off event, as it will include an online knowledge platform that will be active throughout the year and an innovation hub set to bring the main players in the industry together.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211116005046/en/
EIT Urban Mobility is the largest European initiative for the transformation of urban mobility, created by the European Institute of Innovation and Technology (EIT), a body of the European Union. This European initiative benefits of the strategic partnership with Fira de Barcelona by increasing the impact of its European partnership and jointly reaching to a wider audience globally in the mobility scene. Tomorrow.Mobility represents EIT Urban Mobility’s flagship event 2021, showcasing its most promising innovation projects, results, demonstrations, and supported start-ups.
TMWC will bring insights from the global mobility ecosystem gathered under one roof. Being aware of the strong ties that mobility has with other sectors, the event is co-located with Smart City Expo World Congress (SCEWC). More than 350 speakers will be joining alongside hundreds of exhibitors and thousands of attendees. Twelve inspiring congress sessions featuring high-level speakers from both the public and private sector will take place under the umbrella of Tomorrow.Mobility. Speakers include Maria Tsavachidis, CEO of EIT Urban Mobility & President of the Board of Tomorrow.Mobility; Matthew Baldwin, Deputy Director-General for DG MOVE, European Commission; Mark Major, Senior Advisor to the Partnership on Sustainable, Low Carbon Transport (SLoCaT); Carlos Moreno, Scientific director of the Chair Entrepreneurship Territory Innovation, University Panthéon Sorbonne – IAE Paris; and Anna Lisa Boni, Secretary General at Eurocities.
Dr. Maria Tsavachidis, CEO of EIT Urban Mobility & President of the Advisory Board of TMWC stated that “our collaboration with Fira de Barcelona will help expand the network of innovation for urban mobility in Europe and beyond. Our goal is to foster innovation and transformation towards sustainable mobility, to decarbonise mobility, improve people’s quality of life, and make Europe’s economy more competitive. Bringing together the world´s leaders and frontrunners in sustainable mobility under the umbrella of Tomorrow.Mobility is an important steppingstone towards this goal. It will inspire and create new opportunities for our partners, cities, startups, and their innovations ”.
Numerous start-ups supported by EIT Urban Mobility will be showcasing their high-tech solutions at their booths and demo areas, such as: Bia Power (Autonomous Vehicles/Spain), BlockCity (Mobility Services/Hungary), Dashfactory Gmbh (Sensors & Training Data/Germany), Delivers.ai (Last Mile Delivery/Turkey), Vianova (Sensors Data/France), and SmartMonkey (Green Logistics/Spain).
Several EIT Urban Mobility supported innovation projects will be featured at the Central Agora during two different sessions. One session focusing on managing shared public space, and another on how to put Mobility as a Service (MaaS) solutions into practice. Among the EIT Urban Mobility supported projects presented are, FURNISH , which promotes the redesign of public spaces to prevent the spread of COVID-19. Another notable project is HALLO, which creates shared urban consolidation and distribution centres through a series of pilots in Barcelona and Stockholm.
Tomorrow.Mobility, held with the Smart City Expo World Congress (SCEWC), a leading tradeshow & congress on smart cities, has the initial support of over a hundred global companies and trusted institutions amongst which feature the World Bank, the World Economic Forum, the United Nations, Microsoft, Mastercard, ADP (Airports of Paris), the International Association of Ports and Harbours, the Port of Barcelona, Moventia, the RACC and Social Car. The event seeks to tackle the future challenges facing mobility, an industry that will be one of the main drivers of future growth, with a market volume of 60,000 million euros in 2027.
The new event, which will include a congress and exhibition area, will hold a first pilot edition in November and again in 2022. It will address current mobility challenge areas such as micromobility (electric scooters, bicycles), active mobility and the public realm, public transport, mobility providers (car sharing, air taxis), the car industry (electric, connected, and autonomous cars), last mile logistics (e-commerce deliveries, delivery drones), smart infrastructures (fleet management, geolocation, and payment systems), the energy transition towards carbon neutrality and digitisation.
The objective of Tomorrow.Mobility is to go beyond being just an event. The launch of the new show will be accompanied by the creation of a digital content platform with a global reach operating 365 days a year, turning it into the go-to global stage for urban, sustainable, and smart mobility. This platform will allow access to both live events and à la carte contents divided into themes with the aim of facilitating knowledge transfer, training & network.
Practical information
- Dates: 16, 17 & 18 November 2021
- Opening hours: Tue & Wed: 9.00-19.00 CET | Thu: 9.00-17.00 CET
-
Location:
Fira de Barcelona Gran Via – Halls 1 & 2 -
Av. Joan Carles I, 64 - 08908 L’Hospitalet de Llobregat, Barcelona, Spain - EIT Urban Mobility Booth @ Tomorrow.Mobility: Street D, Stand 174
- Event website: www.tomorrowmobility.com
BACKGROUND
About EIT Urban Mobility
EIT Urban Mobility, an initiative of the European Institute of Innovation and Technology (EIT)
, a body of the European Union, aims to accelerate solutions and the transition towards a user-centric, integrated and truly multimodal transport system. As the leading European innovation community for urban mobility, EIT Urban Mobility works to avoid fragmentation by facilitating collaboration between cities, industry, academia, research and innovation to solve the most pressing mobility challenges of cities. Using cities as living labs, its industry, research and university partners will demonstrate how new technologies can work to solve real problems in real cities by transporting people, goods and waste in smarter ways.
For more information visit www.eiturbanmobility.eu .
Follow EIT Urban Mobility on: Linkedin Twitter Facebook Youtube Instagram
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005046/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom